Great work! - given the Type 1/2 patients you mentioned in part 2, seems like going upstream to value based CKD management also enables improved management of the patient funnel for DaVita/Fresenius, as well as potential to improve their overall health before they potentially fall into a value based ESRD bundle - could help reduce total cost of care.
100%. Going upstream and taking on risk can also be higher margin and opens up a larger market. DaVita/Fresenius are both investing in that model and I talked briefly about it here in the context of DaVita's recent earnings announcement https://twitter.com/z_miller4/status/1587072552521850882
Great work! - given the Type 1/2 patients you mentioned in part 2, seems like going upstream to value based CKD management also enables improved management of the patient funnel for DaVita/Fresenius, as well as potential to improve their overall health before they potentially fall into a value based ESRD bundle - could help reduce total cost of care.
100%. Going upstream and taking on risk can also be higher margin and opens up a larger market. DaVita/Fresenius are both investing in that model and I talked briefly about it here in the context of DaVita's recent earnings announcement https://twitter.com/z_miller4/status/1587072552521850882